Signatera Outperforms in Merkel Cell Carcinoma Study, Strengthening Clinical Differentiation

What happened

A prospective study published in JAMA Dermatology found Natera's Signatera test to be a significantly stronger predictor of recurrence than the AMERK antibody test in Merkel cell carcinoma, detecting relapse earlier. This adds to Natera's growing body of clinical evidence supporting Signatera's utility across multiple cancer types. While the data reinforces Signatera's clinical differentiation, the core investment thesis remains tied to operating leverage and MRD volume growth, which the company has yet to demonstrate consistently. Q1 2026 results showed revenue growth of 38.8% YoY but operating losses widened to $(93.5)M as R&D and SG&A outpaced revenue. The stock at $219 prices in sustained MRD compounding, but near-term profitability improvements are needed to justify the valuation.

Implication

The JAMA Dermatology study bolsters Signatera's evidence base, potentially aiding reimbursement and clinician adoption. However, investors should focus on Q2 2026 results for signs of operating leverage—specifically, whether oncology unit growth continues above 10% YoY and operating loss narrows. Without visible progress on expense control, the stock remains vulnerable to competitive pressure from Labcorp and Foundation Medicine. The base case scenario of $235 per share still hinges on salesforce productivity and margin stability, not just clinical accolades.

Thesis delta

The thesis remains unchanged: Natera's clinical differentiation is being confirmed, but the investment case still relies on converting volume growth into operating leverage. The new study adds modest support for the bull case (higher confidence in MRD adoption), but does not address the widening operating loss observed in Q1 2026. The bear case risk of slow expense discipline persists.